In PV, clinical trials targeting autoreactive B-cells including anti-CD20 agents, CAAR-T-cells, BTK inhibitors, and anti-BAFF receptor antibodies are burgeoning fields of research. The gene discussed is TNFRSF13C; the disease is acquired polycythemia vera.